Compare Novo Nordisk A/S (NVO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Prudential Financial Inc — how do they compare? Novo Nordisk A/S trades at $46.19 (market cap $207.85B), while Prudential Financial Inc trades at $121.89 (market cap $42.20B). The key difference: Novo Nordisk A/S is far larger — about 4.9× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.58%). Which is the better fit depends on your goals.
| NVO | PRU | |
|---|---|---|
Market Cap | $207.85B | $42.20B |
Sector | Health | Financials |
52-Week High | $63.98 | $123.93 |
52-Week Low | $35.29 | $92.00 |
Enterprise Value | $222.55B | $70.98B |
Dividend Yield | 3.81% | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
PRU trades at $122.34, up 0.19% today, with a bullish technical signal from moving averages and support near $122. Recent Q2 2026 earnings beat estimates at $4.08 EPS, driven by strong PGIM and international performance. The company maintains a solid net income margin of 6.04% and ROE of 12.46%, with a dividend of $1.40 declared for September 2026. Revenue trends show growth from 2022 lows, reaching $61.0B in 2025.
Outlook is cautiously optimistic with earnings momentum and strategic focus on capital-light operations, but risks include sensitivity to interest rates and China regulatory news. Analysts are mixed with a $113.11 consensus target below current price, suggesting limited upside. Institutional holdings grew, as seen with Assenagon's 379.8% stake increase in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
